Obesity treatment license-out companies Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:23
Jan 21
Jan 21
Obesity royalty economics may worsen.
Global big pharma price competition in obesity treatments is compressing drug prices. Companies that licensed out obesity assets may see future royalty streams and valuations cut because analysts value them off sales-linked royalties. The more obesity drugs become mainstream, the worse the licensing and royalty economics may become.
MED
About Obesity treatment license-out companies Investor Commentary
Across the available history and selected sources, Buzzberg tracks Obesity treatment license-out companies across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kwon Taek-jung.